In Conversation: Gabriel Sanchez
CEO & Co-Founder, Enspectra Health - on steering a medical imaging device company through a decade-long FDA clearance path
The healthcare technology conversation this year keeps returning to the themes raised by Gabriel Sanchez, CEO & Co-Founder, Enspectra Health. In a wide-ranging conversation conducted by TechCrunch, Gabriel laid out a view of the industry that is both candid and immediately useful to the executives, clinicians, and builders who read HealthTech Cube.
The conversation
Steering a medical imaging device company through a decade-long FDA clearance path - and lessons on raising venture money in tightly regulated health markets.
Conversation highlights
Steering a medical imaging device company through a decade-long FDA clearance path
And lessons on raising venture money in tightly regulated health markets
The bigger picture
The AI adoption question runs through every executive conversation in 2026. The evidence base is finally arriving: the largest controlled study of ambient documentation, published in JAMA, found clinicians saved 16 minutes of documentation time per day - but only a third of users hit the usage threshold for maximum benefit (our coverage). Meanwhile Rock Health has stopped labeling AI as a differentiator at all, because every company claims it - which is exactly why operating discipline of the kind described here separates winners from demo-ware.
The capital context matters here. US digital health raised $7.4 billion in H1 2026 with 45% of it concentrated in $100M+ megadeals, and 115 acquisitions made it the busiest M&A run since 2021 (our analysis). In a market this concentrated, the strategies described in this conversation - defensible data, measurable outcomes, disciplined growth - are precisely what separates the funded from the folded.
It is the kind of discussion that separates durable strategy from conference-stage talking points. At Enspectra Health, that thinking translates into daily decisions about where technology genuinely earns its place in care delivery, and where discipline matters more than novelty.
The HTC take
Set against the sector's $7.4 billion funding half-year and accelerating policy agenda, perspectives like this one are the practical map the headlines don't provide.